Comments
Zydus Cadila on Tuesday said it has received approval from the United States Food and Drug Administration (USFDA) to market generic Fluocinonide cream USP, 0.1 per cent, used for the treatment of various skin conditions. The drug will be manufactured at the group’s topical manufacturing facility at Ahmedabad, it added. The group now has 279 approvals and has so far filed over 386 abbreviated new drug applications since the commencement of its filing process, it said in a notice to the stock exchanges. Shares of Cadila Healthcare closed 1.51 per cent lower at ₹274.60 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.